Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1

National Institute on Drug Abuse (NIDA)269 enrolled

Overview

The purpose of this study is to evaluate the Selegiline Transdermal System for the treatment of cocaine dependence.

The study objectives are to assess the efficacy and safety of the Selegiline Transdermal System (STS) in reducing cocaine use in subjects with cocaine dependence. It is hypothesized that selegiline treatment compared to placebo, will be associated with fewer days of cocaine use as assessed by self-report confirmed with urine assays for benzoylecgonine (BE).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

269

Conditions

Cocaine-Related Disorders

Interventions

SelegilineDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male/Female * At least 18 years of age * DSM-4 diagnosis of cocaine dependence * Ability to understand and provide written consent * Female subjects must use acceptable birth control Exclusion Criteria: \- Additional Criteria available during the screening process at the site.

Locations (16)

Tucson VA Medical Center

Tucson, Arizona, United States

Haight-Ashbury Free Clinic

Berkeley, California, United States

Outcomes

Primary Outcomes

Weekly mean proportion of cocaine non-use days

Measured reductions in cocaine and other drug use

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.